[ Pharmaceutical Sciences Asia - ONLINE ]
Print ISSN 2586-8195 E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: 10.29090/psa.2019.02.017.0032Pharm Sci Asia 2019; 46(2), 88-97
 

Performance of the GRACE risk score 2.0 for predicting mortality and Medication Use in Acute Coronary Syndrome patients in Ho Chi Minh city

Thi Minh Hieu Huynh1,Thi Bich Phuong Vo1,Thang Nguyen2,Huong Thao Nguyen1*

1 Department of Clinical Pharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam
2 Department of Pharmacology and Clinical Pharmacy, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam


The Global Registry of Acute Coronary Event (GRACE) risk score was recommended to predict mortality in patients with acute coronary syndrome (ACS). Sufficient use of guidelinerecommended medications decreases post-discharge mortality rate in ACS patients. Evidence on the relationship between risk stratification and medication use in Vietnamese patients with ACS is limited. The objective of this study was to determine the relationship between risk stratification and medication use at discharge in ACS patients. This was a retrospective crosssectional study. Data was collected from medical records of all patients with ACS discharged from The Heart Institute in Ho Chi Minh city, Viet Nam between April and October, 2015. Patients were included if having information of 6-month mortality after discharge. The GRACE risk score version 2.0 was used to stratify patients into three risk subgroups. Prescribing indicators were used to assess the use of medications at discharge. Logistic regression was used to determine the relationship between risk stratification and medication use at discharge. There were 217 patients included. Regarding mortality risk within 6 months after discharge, 94 (43.3%) patients were classified into lowrisk group, 75 (34.6%) patients into moderate-risk group, and 48 (22.1%) patients into high-risk group. At discharge, antiplatelets were used in almost ACS patients (98.8%). The use of β-blockers was suboptimal (64.8%). Only 61.0% of patients were prescribed all guideline-recommended medications. There was a reverse association between risk stratification and medication use at discharge. The low use of β-blockers in ACS patients needs to be investigated, especially in high-risk patients.


Keyword:

Medication use; Prescribing indicators; Acute coronary syndrome; GRACE risk score




Download full paper (PDF File size: 428.50 KB.)





Vol.46
No.4
October - December 2019

See other volume

 


Vol.46
No.3
July - September 2019

See other volume

 


Vol.46
No.2
April - June 2019

See other volume

 


Vol.46
No.1
January - March 2019

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register



    Copyright © 2017
    Faculty of Pharmacy, Mahidol University, THAILAND